Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor Article

Rolfo, Christian, Raez, Luis E, Russo, Antonio et al. (2014). Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor . EXPERT OPINION ON BIOLOGICAL THERAPY, 14(1), 15-26. 10.1517/14712598.2013.843667

Open Access International Collaboration

cited authors

  • Rolfo, Christian; Raez, Luis E; Russo, Antonio; Reguart, Noemi; Garcia Campelo, Rosario; Bronte, Giuseppe; Papadimitriou, Kostantinos; Silvestris, Franco

sustainable development goals

authors

publication date

  • January 1, 2014

webpage

published in

keywords

  • BREAST-CANCER
  • Biotechnology & Applied Microbiology
  • CLINICAL-COURSE
  • CONTROLLED-TRIAL
  • DISEASE
  • Life Sciences & Biomedicine
  • Medicine, Research & Experimental
  • OSSEOUS METASTASES
  • PAIN
  • PROSTATE-CANCER
  • Research & Experimental Medicine
  • SKELETAL COMPLICATIONS
  • SOLID TUMORS
  • Science & Technology
  • ZOLEDRONIC ACID
  • bone metastasis
  • breast cancer
  • denosumab
  • prostate cancer
  • skeletal-related events
  • solid tumors

Digital Object Identifier (DOI)

publisher

  • TAYLOR & FRANCIS LTD

start page

  • 15

end page

  • 26

volume

  • 14

issue

  • 1